Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Nasopharyngeal cancer
Stage/Subtype:  stage IV nasopharyngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 55 for your search:
Start Over
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-HN001, NCI-2014-00635, NCT02179164, RTOG-1305, NCT02135042
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-141, NCI-2014-01268, 2013-003622-86, NCT02105636
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719X2104, NCI-2013-00766, 2011-006017-34, NCT01602315
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, NCT01816984
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4981C00001, NCI-2014-01959, NCT02205333
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2104, NCI-2014-02359, 2014-000579-20, NCT02205398
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
A Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13420, NCI-2012-01213, I4E-MC-JXBB, NCT01063075
Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13418, NCI-2012-01212, I4E-MC-JXBA, NCT01099358
Docetaxel, Cisplatin, and Cetuximab in Treating Patients With Metastatic or Relapsed Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
Cisplatin and Radiation Therapy with or without Dose Boost in Treating Patients with Stage III-IV Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2013.062, NCI-2013-01978, 2013.062, HUM00074305, NCT02031250
Cetuximab, Paclitaxel, and Carboplatin in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC1330, NCI-2015-00334, NCT02124707
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00001, NCI-2015-00060, NCT02207530
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-006, NCI-2014-02188, NCT02213133
Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC-486-NPC-001, NCI-2015-00518, 2014-001745-25, NCT02269943
Pase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4193C00003, NCI-2015-00612, NCT02319044
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OMS-I130, NCI-2015-00840, NCT02345330
Start Over